Diagnostic Subdural EEG-electrode And Subdural hEmatoma (DISEASE)

NCT ID: NCT04211233

Last Updated: 2019-12-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 110 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-20
• Study Completion Date: 2020-12-30

Brief Summary

Epileptic seizures are one of the frequent complications in patients with traumatic brain injury; the incidence lies approximately at 20%. Particularly, acute subdural hematoma (aSDH) is one of the most important predictors for epileptic seizures, which is besides other parameters like age, preoperative Glasgow coma scale, cerebral herniation, hematoma volume and time to operation, associated with worse neurological outcome. In a recent systematic review, the mean incidence of epileptic seizures in aSDH was 28%, whereas one retrospective study focusing on EEG-diagnostic reported very high incidence of epileptiform abnormalities on surface EEG in 87% of patients with aSDH, wherefore the question rises, if the incidence of epileptic seizures is underestimated.

Despite successful evacuation of subdural hematoma, approximately one third of patients show no clinical improvement without medical explanation. Routinely, surface spot EEG is performed to detect epileptic seizures; however the sensitivity is limited due to the skin-bone barrier and the short duration of recording. Furthermore, surface EEG is not always available, for example during the night or at weekends, which is an additional limitation for the loss of treatment timing as well. Spot surface EEG will record for only 20 to 30 minutes in contrast to continuous EEG recordings that are performed for hours or days.

Due to the clinical relevance of epileptic seizures, several studies investigated the benefit of prophylactic antiepileptic treatment. To date, there is only one recommendation from the Brain Trauma Foundation at evidence class II to treat patients with severe traumatic brain injury with prophylactic antiepileptic treatment during the first week. Beyond the interval; there was no clinical benefit for patients selected. Still, there are some limitations´wherefore the clinical use of prophylactic antiepileptic treatment varies between clinicians and countries. At that time, the standard medication was phenytoin which has several side effects, but to date, there are several new intravenous antiepileptic drugs with comparable effect but better safety profile. On the other hand, there was no sifferentiation made between high-risked seizure prone patients, like patients with aSDH, and low-risked patients which is one of the limiting factors to support a general recommendation. Therefore the role of prophylactic antiepileptic treatment is still questionable.

In the clinical routine, invasive EEG-electrodes are commonly used to detect epileptic focus. The benefit of those electrodes is the real time analysis in case of seizure occurrence compared to surface EEG. Moreover, therapeutic effect is directly visible through the monitoring. Therefore the idea of this study was to make a real time analysis possible for patient with TBI, particularly aSDH, to have diagnostic and therapeutic real time monitoring detecting subclinical seizures.

Conditions

Seizures; Subdural Hematoma

Keywords

invasive grid electrode; functional outcome; predictors for seizures

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Invasive subdural arm

Implantation of invasive subdural electrode in patients after surgical treatment of acute subdural hematoma

Group Type: ACTIVE_COMPARATOR

invasive subdural grid electrode

Intervention Type: DEVICE

A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.

Standard treatment arm

Patients with acute subdural hematoma who underwent surgical Treatment and receive Standard medical treatment

Group Type: SHAM_COMPARATOR

Control arm

Intervention Type: OTHER

Standard Treatment based on Brain Trauma Foundation

Interventions

invasive subdural grid electrode

A subdural EEG-electrode (PLATIN 1x4 or 1x6; Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA, Figure 1) will be implanted in the subdural space frontotemporal intraoperatively and diverted separately from the wound area. Afterwards, invasive Monitoring will be performed for 7 days and the grid will be removed simply by pulling out.

Intervention Type: DEVICE

Control arm

Standard Treatment based on Brain Trauma Foundation

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Adult patients (aged ≥18 years)
• Symptomatic aSDH needing operative treatment via craniotomy or craniectomy
• Informed consent

Exclusion Criteria

• Patients with infaust prognosis
• Asymptomatic patients with conservative treatment
• aSDH as a secondary diagnosis
• Concurrent enrollment in any other trial

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Clinic Frankfurt

OTHER

Sponsor Role: lead

Responsible Party

Juergen Konczalla

Pincipal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Goethe University Hospital

Frankfurt am Main, , Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

Sae-Yeon Won, MD

Role: CONTACT

Phone: +496963015295

Email: sae-yeon.won@kgu.de

Juergen Konczalla, MD PhD

Role: CONTACT

Phone: +496963015982

Email: J.konczalla@med.uni-frankfurt.de

Facility Contacts

Anne Sicking

Role: primary

References

Won SY, Freiman TM, Reif PS, Dubinski D, Hattingen E, Herrmann E, Seifert V, Rosenow F, Strzelczyk A, Konczalla J. DIagnostic Subdural EEG electrodes And Subdural hEmatoma (DISEASE): a study protocol for a prospective nonrandomized controlled trial. Neurol Res Pract. 2020 Dec 15;2:50. doi: 10.1186/s42466-020-00096-8. eCollection 2020.

Reference Type: DERIVED

PMID: 33344885 (View on PubMed)

Other Identifiers

DISEASE

Identifier Type: -

Identifier Source: org_study_id